摘要
目的探讨DNA修复基因切除修复交叉互补基因1(ERCC1)多态性与晚期肺腺癌患者接受含铂方案化疗疗效的关系。方法应用实时荧光PCR方法检测72例晚期肺腺癌患者外周血ERCC1基因多态性分布,分析ERCC1 118多态性与晚期肺腺癌患者接受一线含铂方案化疗疗效及总体生存之间的关系。结果总体有效率25%,中位总体生存期为17个月。ERCC1 118多态性与短期疗效无相关性(P>0.05)。与携带ERCC1 118C/C野生纯合基因型患者相比,携带ERCC1118T突变等位基因的患者生存期更长(19个月vs.16个月)(P<0.05)。结论 ERCC1 118T突变等位基因可能与晚期肺腺癌接受含铂方案化疗后的生存时间延长有关。
Objective To investigate the relationship between ERCC1 gene polymorphism and efficacy of platinum-based chemotherapy in patients with advanced lung adenocarcinoma.Methods Real time fluorescent-PCR was used to detecte gene polymorphism in peripheral blood of 72 patients with advanced lung adenocarcinoma.The relationship of ERCC1 118 polymorphism with chemotherapeutic results and overall survival was analyzed in the patients treated with first-line platinumbased chemotherapy.Results The overall effectiveness rate was 25%and median survival time was 17 months.There was no significant correlation between ERCC1 118 polymorphism and the efficacy（P〈0.05）.Compared with ERCC1 118 wild homozygous genotype（C/C）,the median survival time in the patients with allel T of ERCC1 118 was prolonged（19 months vs.16 months）（P〉0.05）.Conclusion Allel T of ERCC1 118 may be related to the prolongation of the overall survival time in the patients with advanced lung adenocarcinoma treated by platinum-based chemotherapy.
出处
《江苏医药》
CAS
2015年第21期2524-2526,F0002,共4页
Jiangsu Medical Journal
基金
国家自然科学基金(81272610)
关键词
DNA修复基因
基因多态性
肺腺癌
切除修复交叉互补基因1
DNA repair gene
Gene polymorphism
Lung adenocarcinoma
Excision repair cross-complementing gene 1
